Allogene Therapeutics Inc

NASDAQ:ALLO  
11.37
-0.21 (-1.81%)
Products, Strategic Combinations

Allogene Therapeutics Agreement With Antion Biosciences For Multiplex Micar Technology

Published: 01/11/2022 14:41 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement With Antion Biosciences for Multiplex Micar™ Technology.
Allogene Therapeutics Inc - Antion Will Exclusively Collaborate With Allogene on Oncology Products for a Defined Period.
Allogene Therapeutics - Will Have Exclusive Worldwide Rights to Commercialize Products Incorporating Antion Technology Developed During Collaboration.
Allogene Therapeutics Inc - Will Pay Antion Developmental and Commercial Milestones and a Single-digit Royalty on Any Product Sales.
Allogene Therapeutics Inc - Will Also Take a Seat on Antion's Board.